GB202115127D0 - Formulations - Google Patents

Formulations

Info

Publication number
GB202115127D0
GB202115127D0 GBGB2115127.9A GB202115127A GB202115127D0 GB 202115127 D0 GB202115127 D0 GB 202115127D0 GB 202115127 A GB202115127 A GB 202115127A GB 202115127 D0 GB202115127 D0 GB 202115127D0
Authority
GB
United Kingdom
Prior art keywords
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2115127.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Priority to GBGB2115127.9A priority Critical patent/GB202115127D0/en
Publication of GB202115127D0 publication Critical patent/GB202115127D0/en
Priority to ARP220102860A priority patent/AR127420A1/es
Priority to US18/703,675 priority patent/US20250281403A1/en
Priority to PE2024000907A priority patent/PE20241192A1/es
Priority to KR1020247016677A priority patent/KR20240099316A/ko
Priority to AU2022369042A priority patent/AU2022369042A1/en
Priority to IL312211A priority patent/IL312211A/en
Priority to CN202280070452.XA priority patent/CN118175989A/zh
Priority to MX2024004873A priority patent/MX2024004873A/es
Priority to CA3235492A priority patent/CA3235492A1/en
Priority to PCT/EP2022/079185 priority patent/WO2023067051A1/en
Priority to EP22809342.3A priority patent/EP4419077A1/en
Priority to GEAP202416521A priority patent/GEAP202416521A/en
Priority to JP2024547821A priority patent/JP2024539502A/ja
Priority to TW111139754A priority patent/TW202330029A/zh
Priority to GEAP202216521A priority patent/GEP20257801B/en
Priority to CL2024001232A priority patent/CL2024001232A1/es
Priority to CONC2024/0006206A priority patent/CO2024006206A2/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
GBGB2115127.9A 2021-10-21 2021-10-21 Formulations Ceased GB202115127D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB2115127.9A GB202115127D0 (en) 2021-10-21 2021-10-21 Formulations
GEAP202216521A GEP20257801B (en) 2021-10-21 2022-10-20 Formulations
MX2024004873A MX2024004873A (es) 2021-10-21 2022-10-20 Composiciones farmaceuticas.
PCT/EP2022/079185 WO2023067051A1 (en) 2021-10-21 2022-10-20 Formulations
PE2024000907A PE20241192A1 (es) 2021-10-21 2022-10-20 Formulaciones
KR1020247016677A KR20240099316A (ko) 2021-10-21 2022-10-20 제제
AU2022369042A AU2022369042A1 (en) 2021-10-21 2022-10-20 Formulations
IL312211A IL312211A (en) 2021-10-21 2022-10-20 Formulations
CN202280070452.XA CN118175989A (zh) 2021-10-21 2022-10-20 制剂
ARP220102860A AR127420A1 (es) 2021-10-21 2022-10-20 Composiciones farmacéuticas
CA3235492A CA3235492A1 (en) 2021-10-21 2022-10-20 Formulations
US18/703,675 US20250281403A1 (en) 2021-10-21 2022-10-20 Formulations
EP22809342.3A EP4419077A1 (en) 2021-10-21 2022-10-20 Formulations
GEAP202416521A GEAP202416521A (en) 2021-10-21 2022-10-20 Formulations
JP2024547821A JP2024539502A (ja) 2021-10-21 2022-10-20 製剤
TW111139754A TW202330029A (zh) 2021-10-21 2022-10-20 配方
CL2024001232A CL2024001232A1 (es) 2021-10-21 2024-04-19 Composiciones farmacéuticas
CONC2024/0006206A CO2024006206A2 (es) 2021-10-21 2024-05-16 Composiciones farmacéuticas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2115127.9A GB202115127D0 (en) 2021-10-21 2021-10-21 Formulations

Publications (1)

Publication Number Publication Date
GB202115127D0 true GB202115127D0 (en) 2021-12-08

Family

ID=78806159

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2115127.9A Ceased GB202115127D0 (en) 2021-10-21 2021-10-21 Formulations

Country Status (17)

Country Link
US (1) US20250281403A1 (https=)
EP (1) EP4419077A1 (https=)
JP (1) JP2024539502A (https=)
KR (1) KR20240099316A (https=)
CN (1) CN118175989A (https=)
AR (1) AR127420A1 (https=)
AU (1) AU2022369042A1 (https=)
CA (1) CA3235492A1 (https=)
CL (1) CL2024001232A1 (https=)
CO (1) CO2024006206A2 (https=)
GB (1) GB202115127D0 (https=)
GE (2) GEAP202416521A (https=)
IL (1) IL312211A (https=)
MX (1) MX2024004873A (https=)
PE (1) PE20241192A1 (https=)
TW (1) TW202330029A (https=)
WO (1) WO2023067051A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201209096D0 (en) 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂

Also Published As

Publication number Publication date
CA3235492A1 (en) 2023-04-27
US20250281403A1 (en) 2025-09-11
IL312211A (en) 2024-06-01
PE20241192A1 (es) 2024-06-03
GEAP202416521A (en) 2024-07-25
CO2024006206A2 (es) 2024-05-30
AR127420A1 (es) 2024-01-24
CL2024001232A1 (es) 2024-09-13
WO2023067051A1 (en) 2023-04-27
KR20240099316A (ko) 2024-06-28
MX2024004873A (es) 2024-05-06
JP2024539502A (ja) 2024-10-28
GEP20257801B (en) 2025-09-25
EP4419077A1 (en) 2024-08-28
TW202330029A (zh) 2023-08-01
CN118175989A (zh) 2024-06-11
AU2022369042A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
IL287224A (en) New formulations containing melphalan
IL290356A (en) Formulations for Resotide
GB202117828D0 (en) New formulations
GB201915094D0 (en) New formulations
GB201904338D0 (en) Fluorouracil-containing formulations
IL284691A (en) formulations
GB202007546D0 (en) Formulation
GB202103785D0 (en) Formulations
GB202018889D0 (en) Formulations
GB202009684D0 (en) Formulations
GB202009685D0 (en) Formulations
IL307849A (en) Sutorsive formulation
GB202108165D0 (en) Formulation
GB202102636D0 (en) Formulation
GB201910092D0 (en) New formulations
GB202115121D0 (en) Formulations
GB202115127D0 (en) Formulations
GB202103780D0 (en) Formulations
GB202103762D0 (en) Formulations
GB202018251D0 (en) Formulations
GB202018250D0 (en) Formulations
GB202108259D0 (en) Novel formulations
IL321617A (en) Formulations of bazuclatinib
GB202315863D0 (en) Formulations
GB202307059D0 (en) Formulations

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)